Evaxion Biotech Net Worth
Evaxion Biotech Net Worth Breakdown | EVAX |
Evaxion Biotech Net Worth Analysis
Evaxion Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Evaxion Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Evaxion Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Evaxion Biotech's net worth analysis. One common approach is to calculate Evaxion Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Evaxion Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Evaxion Biotech's net worth. This approach calculates the present value of Evaxion Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Evaxion Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Evaxion Biotech's net worth. This involves comparing Evaxion Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Evaxion Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Evaxion Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evaxion Biotech's net worth research are outlined below:
| Evaxion Biotech AS generated a negative expected return over the last 90 days | |
| Evaxion Biotech AS has high historical volatility and very poor performance | |
| Evaxion Biotech AS may become a speculative penny stock | |
| Evaxion Biotech AS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 73 K. Net Loss for the year was (22.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (17.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06. | |
| Evaxion Biotech AS has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Evaxion Biotech stock hits 52-week low at 1.31 - Investing.com |
Evaxion Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evaxion Biotech AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evaxion Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of April 2024 Upcoming Quarterly Report | View | |
| 29th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Evaxion Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evaxion Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evaxion Biotech AS backward and forwards among themselves. Evaxion Biotech's institutional investor refers to the entity that pools money to purchase Evaxion Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 483 K | Invst Llc | 2024-06-30 | 54 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Beacon Capital Management, Llc | 2024-09-30 | 4.9 K | Jpmorgan Chase & Co | 2024-06-30 | 2.2 K | Rhumbline Advisers | 2024-06-30 | 290 | Southstate Corp | 2024-09-30 | 4.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Follow Evaxion Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.28 M.Market Cap |
|
Project Evaxion Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.72) | (1.80) | |
| Return On Capital Employed | (3.82) | (3.63) | |
| Return On Assets | (1.72) | (1.80) | |
| Return On Equity | 4.68 | 4.91 |
When accessing Evaxion Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Evaxion Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evaxion Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Evaxion Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evaxion Biotech AS. Check Evaxion Biotech's Beneish M Score to see the likelihood of Evaxion Biotech's management manipulating its earnings.
Evaluate Evaxion Biotech's management efficiency
Evaxion Biotech AS has return on total asset (ROA) of (0.6945) % which means that it has lost $0.6945 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.028) %, meaning that it created substantial loss on money invested by shareholders. Evaxion Biotech's management efficiency ratios could be used to measure how well Evaxion Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 4.91 in 2024, whereas Return On Tangible Assets are likely to drop (1.80) in 2024. At this time, Evaxion Biotech's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.73) | (1.82) | |
| Tangible Book Value Per Share | (1.73) | (1.82) | |
| Enterprise Value Over EBITDA | (1.12) | (1.18) | |
| Price Book Value Ratio | (3.97) | (4.16) | |
| Enterprise Value Multiple | (1.12) | (1.18) | |
| Price Fair Value | (3.97) | (4.16) | |
| Enterprise Value | 27.6 M | 26.3 M |
Evaluating the management effectiveness of Evaxion Biotech allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Evaxion Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 3.7128 | Revenue 3.3 M | Revenue Per Share 0.713 | Return On Equity (8.03) |
Evaxion Biotech Earnings per Share Projection vs Actual
Evaxion Biotech Corporate Management
| DMSC MD | Chief Officer | Profile | |
| Christian MSc | Chief Officer | Profile | |
| Jrgen EMBA | Head Board | Profile | |
| Bo Karmark | Chief Officer | Profile | |
| Jesper Nissen | Chief Officer | Profile | |
| Thomas Schmidt | Interim Officer | Profile |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.